Parkinson’s disease (PD) was the first neurological disease to b e modelled in animals. Early models of PD used toxins which selectively targeted dopaminergic neurons, such as reserpine, 6 -hydroxydopamine, and 1 -methyl-4-phenyl-1,2,3,6tetrahydropyridine. These initial models have greatly contributed to the current understanding of the pathogenesis of PD and have proven to be valuable tools in the development of novel therapeutic approaches, but have failed to mimic important characteristics of PD. Recently, it has been found that chronic systemic exposure to the pesticide rotenone can reproduce specific features of PD in rodents. Moreover, the association of a-synuclein mutations with some cases of familial PD have motivated the development of genetic models of PD in mice and Drosophila. The present essay gives a brief survey of the clinics and pathophysiology of PD, discusses the different animal models of PD currently available, and briefly compares the suitability the rodents and primates as models for human PD.
Table of Contents
1. Introduction
2. Parkinson’s disease
3. Animal models of Parkinson’s disease: General considerations
3.1 Why use animal models?
3.2 The ideal animal model of PD
3.3 The reserpine model
4. The 6-hydroxydopmanine model
4.1 General considerations
4.2 Mechanism of action
4.3 Motor deficits
4.4 Drawbacks of the 6-OHDA model
5. The MPTP model
5.1 General considerations
5.2 Mechanism of action
5.3 MPTP-induced phenotype
6. Novel models of Parkinson's disease
6.1 The rotenone model
6.2 The BH4 model
7. Genetic models of Parkinson's disease
8. Rodents or primates?
9. Conclusions
Research Objectives and Topics
This essay aims to provide a comprehensive survey of the clinical manifestations and pathophysiology of Parkinson's disease (PD) while critically evaluating the various animal models currently available for research. By comparing different experimental approaches—ranging from traditional neurotoxin-based methods to modern genetic models—the work assesses the suitability of rodents versus primates in replicating the neuropathological and phenotypic features of human PD to facilitate the development of novel therapeutic strategies.
- Pathophysiology and clinical features of Parkinson's disease
- Evaluation of neurotoxin-based models (6-OHDA, MPTP, Rotenone)
- Role of genetic factors and transgenic models in PD research
- Comparative analysis of rodents and primates as experimental subjects
- Challenges in modeling progressive neurodegeneration and motor deficits
Excerpt from the Book
The MPTP model
In 1982, a group of drug-addicts in California developed a severe subacute onset of severe, L-DOPA responsive parkinsonian symptomatology. Subsequent examination revealed that the syndrome was caused by a self-administered synthetic heroin analogue that had been contaminated by a byproduct, called 1-methyl-4-phenyl-1,2,3,6-tetrahydropyidine (MPTP), during manufacture (Langston et al. 1983). Today, the MPTP treated primate is considered the most effective experimental model of PD (Beal et al. 2001), while, with the exception of some strains of mice, most rodent species are insensitive to MPTP toxicity (Gerlach and Riederer 1996). Acute MPTP exposure leads to specific degeneration of the nigrostriatal pathway with 50-93% cell loss in the SNPC and more than 99% in the striatum (Hantraye et al. 1993). Interestingly, in monkey, the topology of nigral lesion after MPTP treatment is similar to that observed in human PD, with the lateral part of the SNPC being more affected than the medial part (Varastet et al. 1994). As in human PD, MPTP also causes degeneration in other neuronal cell populations, such as the locus coeruleus (Forno et al., 1986, 1993), and the ventral tegmental area (German et al. 1988).
Summary of Chapters
1. Introduction: Outlines the historical context of animal modeling for Parkinson's disease and defines the scope of the essay regarding available research models.
2. Parkinson’s disease: Describes the clinical symptoms, pathology, and underlying nigrostriatal dopaminergic degeneration characteristic of the disease.
3. Animal models of Parkinson’s disease: General considerations: Discusses the rationale for using animal models and defines the criteria for an ideal research model, including a brief overview of the reserpine model.
4. The 6-hydroxydopmanine model: Analyzes the mechanism, motor outcomes, and limitations of using 6-OHDA to induce lesions in the nigrostriatal pathway.
5. The MPTP model: Explores the discovery, neurotoxic mechanism, and clinical relevance of MPTP, particularly in primate models.
6. Novel models of Parkinson's disease: Reviews newer approaches to modeling PD, specifically the rotenone model and the potential of the BH4 model.
7. Genetic models of Parkinson's disease: Examines how transgenic mice and Drosophila are used to study the genetic components and alpha-synuclein contributions to PD.
8. Rodents or primates?: Compares the biochemical and physiological differences between species and their impact on the predictive power of experimental data.
9. Conclusions: Synthesizes the findings and emphasizes the importance of selecting models based on the specific research question and the limitations of current paradigms.
Keywords
Parkinson's disease, 6-hydroxydopamine, MPTP, rotenone, nigrostriatal pathway, dopamine, neurodegeneration, animal models, alpha-synuclein, genetic models, pathophysiology, motor deficits, oxidative stress, primates, rodents.
Frequently Asked Questions
What is the primary focus of this work?
The essay provides a detailed review of current animal models used to study Parkinson's disease, focusing on how well these models replicate the clinical and pathological features observed in human patients.
What are the main research areas covered?
The text covers traditional neurotoxin-induced models, the role of oxidative stress, recent advancements in genetic models, and a comparative evaluation of biological differences between experimental species.
What is the ultimate goal of the research presented?
The objective is to guide researchers in choosing appropriate animal models for their specific experimental paradigms, thereby improving the understanding of PD pathogenesis and facilitating the testing of therapeutic interventions.
Which scientific methods are analyzed?
The work analyzes various induction methods, including toxin administration (6-OHDA, MPTP, rotenone), genetic manipulation (transgenic models), and specific pharmacological challenges to the nigrostriatal system.
What does the main body of the text discuss?
The main body examines individual animal models in depth—including their mechanisms of toxicity, the phenotypes they produce, and their specific drawbacks—followed by a comparison between rodents and primates.
What are the characterizing keywords of this study?
Key terms include Parkinson's disease, neurodegeneration, 6-OHDA, MPTP, nigrostriatal pathway, and experimental animal models.
Why is the 6-OHDA model considered limited?
The 6-OHDA model is limited because it causes an acute, rather than progressive, loss of neurons and fails to induce characteristic Lewy-body pathology or affect non-dopaminergic cell populations.
Why do researchers distinguish between rodents and primates when modeling PD?
The author highlights significant differences in brain size, innervation capacity, and monoamine biochemistry, which limit the transferability of rodent-derived findings to human clinical applications.
- Arbeit zitieren
- PhD Burkhard Niewoehner (Autor:in), 2003, Animal Models of Parkinson´s Disease, München, GRIN Verlag, https://www.hausarbeiten.de/document/48123
